Web Exclusives

At the National Organization of Rheumatology Managers (NORM) 2017 Annual Conference, September 14-16, in Kansas City, MO, our expert speakers and educational sessions will help you further develop your management skills and successfully lead your practice into the future. Read Article ›

“We think this is one of the biggest survival gains ever reported in a trial of an adult solid tumor,” said Nicholas D. James, PhD, BSc, MBBS, FRCP, FRCR. Read Article ›

The National Organization of Rheumatology Managers (NORM) is pleased to announce that we have joined forces with several patient and provider groups, including the Coalition of State Rheumatology Organizations (CSRO), the American College of Rheumatology, the Global Healthy Living Foundation, the Rheumatology Nurses Society, and the Arthritis Foundation (AF) to form the Alliance for Transparent and Affordable Prescriptions (ATAP). Read Article ›

Dr Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs, and as Senior Advisor to the FDA Commissioner. Read Article ›

“This study’s findings—that adding antiandrogen therapy to the radiation typically used against recurrence reduces the incidence of metastasis, death from prostate cancer and overall deaths—will change the standard of care for patients experiencing a postoperative recurrence,” Dr Shipley added.

Read Article ›

Rheumatology Practice Management (RPM) will be providing a valuable new resource to our readers. Beginning in June, we will be featuring a Coding Corner section, with the goal of helping practice managers stay informed of pertinent issues concerning medical billing and coding, denials, and appeal protocols.

Read Article ›

In the coming year, NORM and Rheumatology Practice Management will strive to provide practice managers with the information and resources they need to deliver quality patient care.

Read Article ›

The US Food and Drug Administration (FDA) has approved etanercept-szzs, a biosimilar to etanercept (Enbrel), for the treatment of multiple inflammatory diseases, according to an announcement by the organization. The biosimilar injection has been approved to treat patients with moderate-to-severe rheumatoid arthritis; moderate-to-severe polyarticular juvenile idiopathic arthritis; active psoriatic arthritis; active ankylosing spondylitis; and chronic, moderate-to-severe plaque psoriasis. Read Article ›

In our last issue, we discussed ways for rheumatology practice managers, physicians, healthcare professionals, and patients to get involved and raise awareness about concerns surrounding the Medicare Part B Drug Payment Model Proposed Rule by the Centers for Medicare & Medicaid Services (CMS). Andrea and I wanted to share our Washington, DC, experience and encourage our membership to continue to oppose the Part B Drug Demonstration Project. Read Article ›

Immediate-release opioid analgesics will now require boxed warnings regarding the serious risks for abuse, addiction, overdose, neonatal opioid withdrawal syndrome (NOWS), and death associated with the drugs, according to an announcement by the US Food and Drug Administration (FDA). This is the latest in a number of steps recently outlined by the FDA in their bid to reassess their approach to opioid medications. Read Article ›

Ixekizumab (Taltz) has been approved by the US Food and Drug Administration (FDA) for use in patients with moderate-to-severe plaque psoriasis, the agency has announced. Administered as an injection, ixekizumab is an antibody that binds and inhibits the inflammatory response of the inflammation-causing interleukin-17A protein. Read Article ›

The US Food and Drug Administration (FDA) announced the approval of Inflectra (infliximab-dyyb)—a biosimilar to Remicade (infliximab)—for patients with chronic severe plaque psoriasis, and active ankylosing spondylitis or psoriatic arthritis. The biosimilar is also indicated for adult patients with moderately to severely active ulcerative colitis who have inadequately responded to standard therapy; in combination with methotrexate for patients with moderately to severely active rheumatoid arthritis; and patients aged ≥6 years with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Inflectra is the second biosimilar approved by the FDA. Read Article ›

Page 3 of 5

Subscribe to
Urology Practice Management

Stay up to date with urology news & updates by subscribing to recieve the free UPM print publications or weekly e‑Newsletter.

I'd like to recieve: